Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD


KENSINGTON, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the initiation of a Phase 2 study (eDREAM; NCT06659549) with GAL-101 eye drops in patients with dry age-related macular degeneration (dry AMD), a leading cause of adult blindness. The randomized, double-blind, placebo-controlled multicenter study will evaluate the efficacy and safety of GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

See more here:
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Related Posts